I-Mab anticipates its first product launch in 2021–2022, for the anti-CD38 monoclonal antibody TJ202, which is currently in a phase 3 trial and a registrational trial in parallel in Greater ...

“This is a natural place for a platform proof-of-concept, because monoclonal antibodies against CD38 have been approved for the indication, and anti-CD3 antibodies have been shown to redirect ...

and one anti-CD38 monoclonal antibody. NICE recommended Elrexfio and Tecvayli with what it calls 'optimised' guidance, which means that they can be used with modifications to the MHRA-approved ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further ...

of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J ...

CD38 monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies are pivotal in multiple myeloma management, offering deep responses and manageable toxicities. Comprehensive molecular ...